vTv Therapeutics joins the oral drug market for type one diabetics
vTv Therapeutics announced positive phase two results for its oral antidiabetic drug, TTP-399. Credit: Iryna Imago on Shutterstock.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more